tldrdailynews.com logo

FDA Approves Merck’s RSV Prevention Treatment for Infants

1 min read
Source: Merck.com
FDA Approves Merck’s RSV Prevention Treatment for Infants
Photo: Merck.com
TL;DR

The FDA has approved Merck's ENFLONSIA, a monoclonal antibody for preventing RSV lower respiratory tract disease in infants during their first RSV season, offering a single, weight-independent dose providing protection for about 5 months based on clinical trial success.

Topics:top-newshealthcare#enflonsia#healthcare#infant-prevention#merck#monoclonal-antibody#rsv
Share this article
  1. U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season  Merck.com
  2. FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca  CNBC
  3. Merck Says It Wins US Approval for Shot to Prevent Infant RSV  Bloomberg
  4. US FDA approves Merck's RSV antibody for infants  Reuters
  5. Merck’s RSV antibody treatment for infants is approved by FDA  statnews.com

Want the full story? Read the original reporting

Read on Merck.com